News / Uncategorized
This next-generation CRISPR company is on the rise…
This next-generation CRISPR company is on the rise…
August 21, 2023
Scribe Therapeutics – a company spun out of UC Berkeley – just raised $100 million in a Series B venture capital (VC) round. This is a follow-on to Scribe’s $20 million Series A round back in October of last year. I have been tracking Scribe since the company got started back in 2019.
That’s because Jennifer Doudna is one of its founders. If we remember, Doudna won the Nobel Prize last year for her early work on CRISPR genetic editing technology. Anything she is working on is worth keeping an eye on. And Scribe’s approach is interesting. The company is using computational biology to create new enzymes for use in CRISPR therapies. Enzymes are the delivery mechanism for getting the therapy to the cells that need to be edited.
So Scribe’s focus is to optimize CRISPR enzymes. This will open the door to all kinds of new therapies. Each enzyme will be tailored for different disease targets. And Scribe’s first engineered enzyme is called CasX. CasX is smaller than the Cas9 enzyme that many of the first-generation CRISPR therapies use. Scribe believes that the CasX enzyme will be perfectly suited to tackle neurodegenerative diseases that have been extremely difficult to treat with traditional therapies.
I’m very excited to see the company’s full development pipeline when it is released. And what’s remarkable here is that there is absolutely no competition in the space. The development of new CRISPR enzymes represents a greenfield opportunity. It’s a new technology that will create cures for diseases that have been untreatable up to this point. We will definitely want to keep a close eye on Scribe going forward.
I suspect that this company will move quickly given its approach. This company is doing some great work. Let’s make sure we have it on our early stage watchlist.
Share this article:
More in Uncategorized:
Hedge funds and banks typically use multiple time frames for intraday trading
Hedge funds and banks typically use multiple time frames for intraday trading, as this allows them to gain a comprehensive...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
August 30, 2024
Nvidia Earnings Call: A Record Quarter with a Twist
Nvidia’s Q2 earnings call was a mixed bag, with the company reporting a record quarter but also revealing a drop...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 29, 2024
Nvidia Earnings: A Critical Moment for Big Tech
As we approach Nvidia’s earnings report, the tech world holds its breath. This isn’t just about one company’s performance; it’s...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
August 28, 2024
The Sleeping Giant: Why Intel is an Undervalued Stock
As the world’s largest semiconductor company, Intel (INTC) has long been a household name in the tech industry. However, despite...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 23, 2024
The Trillion Dollar Addiction...
The Trillion Dollar Addiction That Amazon, Google, Meta and Microsoft Will Be Selling Next Year As I discussed in my...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 19, 2024
What is an AI Agent? What Can It Do For You? Where Can You Get One?
As I discussed with my tribe during our recent stock talk, I’m excited to share with you the concept of...
This next-generation CRISPR company is on the rise…
August 18, 2024